feed,title,long_url,short_url
Benzinga,Forma Therapeutics' Olutasidenib Achieves 33% Remission Rate In Acute Myeloid Leukemia Patients,https://benzinga.com/general/biotech/21/05/21217614/forma-therapeutics-olutasidenib-achieves-33-remission-rate-in-acute-myeloid-leukemia-patients,https://j.mp/3u8YJJ0
